A Friend-ly New Resource for Biomarker Validation?
This article was originally published in Start Up
Executive Summary
Merck is helping one of its top executives launch a new nonprofit venture, called Sage, which will develop disease models and provide an open access platform for researchers to gauge the effects of perturbing them. Pharma has never really supported the diagnostics industry apart from its own internal need for biomarkers. But along with supporting drug development, Sage could actually go to that very kind of diagnostics development that pharma has not wanted to do in the past.